An official website of the United States government
Home
Name
Vandetanib
Alternate Names
AZD6474
Caprelsa
Zactima
ZD 6474
ZD-6474
ZD6474
Abbreviations
None
Category
Chemotherapy
Subcategory
Angiogenesis inhibitor
NSC Number
None
Primary Site
Histology
None
Remarks
April 6, 2011: Received FDA approval for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable (non-operable) locally advanced or metastatic disease.
Phase III Lung
Vascular endothelial cell growth factor receptor tyrosine kinase (VEGFR TKI) inhibitor. AstraZeneca.
Phase III Lung
Vascular endothelial cell growth factor receptor tyrosine kinase (VEGFR TKI) inhibitor. AstraZeneca.
Coding
This drug should be coded
